Foamix Pharmaceuticals Ltd. (NASDAQ:FOMX) released its quarterly earnings results on Tuesday. The specialty pharmaceutical company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.03), Briefing.com reports. Foamix Pharmaceuticals had a negative return on equity of 39.20% and a negative net margin of 823.74%. The company had revenue of $0.90 million for the quarter, compared to analyst estimates of $0.90 million. During the same quarter last year, the company earned ($0.19) EPS. The firm’s revenue for the quarter was down 64.6% on a year-over-year basis.

Foamix Pharmaceuticals (NASDAQ FOMX) traded up $0.09 on Tuesday, hitting $5.68. 76,500 shares of the company traded hands, compared to its average volume of 166,577. Foamix Pharmaceuticals has a 52-week low of $4.03 and a 52-week high of $11.27.

TRADEMARK VIOLATION WARNING: This news story was reported by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another website, it was illegally copied and reposted in violation of US and international trademark & copyright laws. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/14/foamix-pharmaceuticals-ltd-fomx-releases-quarterly-earnings-results-misses-estimates-by-0-03-eps.html.

Several research analysts recently weighed in on FOMX shares. Credit Suisse Group AG restated a “buy” rating and set a $9.00 price target on shares of Foamix Pharmaceuticals in a research report on Wednesday, July 19th. HC Wainwright started coverage on shares of Foamix Pharmaceuticals in a research report on Thursday, August 24th. They set a “buy” rating and a $12.00 price target for the company. Finally, Zacks Investment Research downgraded shares of Foamix Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Tuesday, October 3rd.

Foamix Pharmaceuticals Company Profile

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions.

Earnings History for Foamix Pharmaceuticals (NASDAQ:FOMX)

Receive News & Ratings for Foamix Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Foamix Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.